ID
22108
Descripción
The present pharmacokinetic study is designed to assess the pharmacokinetics of RSG XR as monotherapy in patients with mild Alzheimer's disease (AD) as such information will not be obtained from the current phase III trials . The study aims to enroll fourteen patients (seven of each APOE genotype). Each patient will receive a single oral dose of 4mg of RSG XR in the morning under fasted conditions and PK samples will be taken up to 36h. GSK Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT00688207?term=NCT00688207&rank=1
Link
https://clinicaltrials.gov/ct2/show/NCT00688207?term=NCT00688207&rank=1
Palabras clave
Versiones (2)
- 8/5/17 8/5/17 -
- 20/5/17 20/5/17 -
Subido en
20 de mayo de 2017
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY-NC 3.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
Follow-Up Urinalysis Mild Alzheimer's Disease to Assess the of Extended Release Formulation of Rosiglitazone NCT00688207 / GSK-AVA109941
Follow-Up Urinalysis Mild Alzheimer's Disease to Assess the of Extended Release Formulation of Rosiglitazone NCT00688207 / GSK-AVA109941
Similar models
Follow-Up Urinalysis Mild Alzheimer's Disease to Assess the of Extended Release Formulation of Rosiglitazone NCT00688207 / GSK-AVA109941
C0042014 (UMLS CUI-2)
C0042014 (UMLS CUI [1,2])
C2826772 (UMLS CUI-2)
C0042014 (UMLS CUI [1,2])
C0042014 (UMLS CUI [1,2])
C2826772 (UMLS CUI-2)
C0042014 (UMLS CUI [1,2])
C0042014 (UMLS CUI [1,2])